Dergiler / Turkish archives of pediatrics (Online) / 2021 / Cilt: 56 - Sayı: 4

The Ideal Timing of Bedside Surgical Ligation of Patent Ductus Arteriosus in Premature Babies Less Than 30 Gestational Weeks

Sayfa
300–307
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Prolonging pharmacologictreatment in order to avoid surgery increases the risk of severe bronchopulmonary dysplasiaand prolongs hospital stay.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: The aim of our study is to determine the relationship between exposure to hemodynamicallysignificant patent ductus arteriosus and morbidities in premature babies, the optimalnumber of pharmacologic treatment cycles, and ideal ductus ligation timing.Materials and Methods: The study was a retrospective single-center study conducted in a3-year period between July 2017 and June 2020.
📊
Temel Bulgular & Veri:Premature babies, born ≤30 weeks of gestationand transferred to our unit for bedside ductus ligation, were included in the study.
💡
Sonuç & Katkı:Prolonging pharmacologictreatment in order to avoid surgery increases the risk of severe bronchopulmonary dysplasiaand prolongs hospital stay.
🔬Tür:Araştırma Makalesi
📍Kapsam:2017 Verileri
⚙️Değişkenler:Alan Parametreleri

Özet

Objective: The aim of our study is to determine the relationship between exposure to hemodynamicallysignificant patent ductus arteriosus and morbidities in premature babies, the optimalnumber of pharmacologic treatment cycles, and ideal ductus ligation timing.Materials and Methods: The study was a retrospective single-center study conducted in a3-year period between July 2017 and June 2020. Premature babies, born ≤30 weeks of gestationand transferred to our unit for bedside ductus ligation, were included in the study. The subjectswere divided into 2 groups; Group A consisted of the patients who received ≥3 pharmacologictreatment cycles, and group B consisted of the patients who received ≤2 cycles. The groupswere compared according to preoperative and postoperative features. The main outcome ofthe study was the presence of severe bronchopulmonary dysplasia. The secondary outcomeswere specified as the length of stay in the neonatal intensive care unit and the duration of invasivemechanical ventilation (MV).Results: The study group consisted of 24 patients. There were 10 patients in group A and14 patients in group B. The mean gestational week and the mean birthweight were found tobe 26,7 ± 2.2 weeks and 928 ± 190 g, respectively. The incidence of severe bronchopulmonarydysplasia was significantly higher in group A (70% vs. 14.3%; P = .019). Post-ligation invasiveMV, duration, and length of stay in the intensive care unit were found to be significantly longerin group A. None of the patients had hemodynamic disturbances or complications during andafter the operation.Conclusions: Bedside surgical ductus ligation is a safe procedure. Prolonging pharmacologictreatment in order to avoid surgery increases the risk of severe bronchopulmonary dysplasiaand prolongs hospital stay.

🔖

Bu Makaleye Atıf Yap

ZÜBARİOĞLU, A. U., YILDIRIM, Ö., ZEYBEK, C., BALABAN, İ., ALİYEV, B., YAZICIOĞLU, V., TUTAK, E., DURSUN, M., ÜNAL, E. T., KARA, N. (2021). The Ideal Timing of Bedside Surgical Ligation of Patent Ductus Arteriosus in Premature Babies Less Than 30 Gestational Weeks. Turkish archives of pediatrics (Online), Cilt: 56 - Sayı: 4, 300–307. https://ajindex.com/articles/369994

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

  1. Evans N. Management of the patent ductus arteriosus in the very pre-term infant. Paediatr Child Health. 2011
  2. 21(6):247-253. [CrossRef] 2. Nemerofsky SL, Parravicini E, Bateman D, et al. The ductus arteriosus rarely requires treatment in infants >1000 grams. Am J Perinatol. 2008
  3. 25(10):661-666. [CrossRef] 3. Clyman RI, Couto J, Murphy GM. Patent ductus arteriosus: Are current neonatal treatment options better or worse than no treatment at all? Semin Perinatol. 2012
  4. 36(2):123-129. [CrossRef] 4. Jhaveri N, Moon-Grady A, Clyman RI. Early surgical ligation versus a conservative approach for management of patent ductus arteriosus that fails to close after indomethacin treatment. J Pediatr. 2010
  5. 157(3):381.e1-387.e1. [CrossRef] 5. Sosenko IR, Fajardo MF, Claure N, Bancalari E. Timing of patent ductus arteriosus treatment and respiratory outcome in premature infants: A double-blind randomized controlled trial. J Pediatr. 2012
  6. 160(6):929.e1-935.e1. [CrossRef] 6. Mirea L, Sankaran K, Seshia M, et al. Treatment of patent ductus arteriosus and neonatal mortality/morbidities: Adjustment for treatment selection bias. J Pediatr. 2012
  7. 161(4):689.e1-694.e1. [CrossRef] 7. Clyman RI. The role of patent ductus arteriosus and its treatments in the development of bronchopulmonary dysplasia. Semin Perinatol. 2013
  8. 37(2):102-107. [CrossRef] 8. Jansen EJS, Dijkman KP, van Lingen RA, et al. Using benchmarking to identify inter-centre differences in persistent ductus arteriosus treatment: can we improve outcome? Cardiol Young. 2017
  9. 27(8):1488-1496. [CrossRef] 9. Edstedt Bonamy AK, Gudmundsdottir A, Maier RF, et al. Patent ductus arteriosus treatment in very preterm infants: A European populationbased cohort study (EPICE) on variation and outcomes. Neonatology. 2017
  10. 111(4):367-375. [CrossRef] 10. Fraisse A, Bautista-Rodriguez C, Burmester M, Lane M, Singh Y. Transcatheter closure of patent ductus arteriosus in infants with weight under 1,500 grams. Front Pediatr. 2020
  11. 558256. [CrossRef] 11. Köksal N, Aygün C, Uras N. Turkish Neonatal Society guideline on the management of patent ductus arteriosus in preterm infants. Turk Pediatr Ars. 2018
  12. 53(Suppl 1):S76-S87. [CrossRef] 12. Singh Y, Fraisse A, Erdeve O, Atasay B. Echocardiographic diagnosis and hemodynamic evaluation of patent ductus arteriosus in extremely low gestational age newborn (ELGAN) infants. Front Pediatr. 2020
  13. 573627. [CrossRef] 13. Camargo Barros Rocha DA, Marson FAL, Almeida CCB, Almeida Junior AA, Ribeiro JD. Asso